EPISODE · Apr 3, 2026 · 1 MIN
A New Biological Front in MS: Fenebrutinib For Primary Progressive Multiple Sclerosis (PPMS)
from TheBrief.Health · host TheBrief.Health
Fenebrutinib, an oral BTK inhibitor, shows non-inferiority to ocrelizumab in PPMS, targeting CNS inflammation, reducing infusion burden, and expanding equitable, scalable progressive multiple sclerosis care.
What this episode covers
Fenebrutinib, an oral BTK inhibitor, shows non-inferiority to ocrelizumab in PPMS, targeting CNS inflammation, reducing infusion burden, and expanding equitable, scalable progressive multiple sclerosis care.
NOW PLAYING
A New Biological Front in MS: Fenebrutinib For Primary Progressive Multiple Sclerosis (PPMS)
No transcript for this episode yet
Similar Episodes
Apr 21, 2026 ·13m
Apr 19, 2026 ·16m
Apr 17, 2026 ·13m
Apr 13, 2026 ·11m
Apr 11, 2026 ·16m